Chemical formula: C₁₉H₂₃ClN₂ Molecular mass: 314.852 g/mol PubChem compound: 2801
The therapeutic activity of clomipramine is believed to be based on its ability to inhibit the neuronal re-uptake of noradrenaline (NA) and serotonin (5-HT) released in the synaptic cleft, with inhibition of 5-HT reuptake being the more important of these activities.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N06AA04 | Clomipramine | N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ANAFRANIL Prolonged-release, film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Clomipramine is an active ingredient of these brands:
United States (US)
Austria (AT)
Brazil (BR)
Canada (CA)
Cyprus (CY)
Ecuador (EC)
Estonia (EE)
Finland (FI)
France (FR)
Germany (DE)
Hong Kong (HK)
Ireland (IE)
Japan (JP)
Lithuania (LT)
Malta (MT)
Mexico (MX)
Nigeria (NG)
Poland (PL)
Romania (RO)
South Africa (ZA)Spain (ES)
Tunisia (TN)
Turkey (TR)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
